肾透明细胞癌患者术前血清高敏C反应蛋白和降钙素原水平与肿瘤病理分期、分级的相关性研究  

Relationship between preoperative high sensitive C-reactive protein,procalcitonin levels and tumor stage,tumor grade in patients with clear cell renal cell carcinoma

作　　者：岳根全[1] 白立刚[1] 王国强[1] 黄勇[1] 闫骏[1] YUE Gen-quan;BAI Li-gang;WANG Guo-qiang;HUANG yong;YAN Jun(Department of Urology,First Hospital of Inner Mongolia Medical University, Hohhot 010050, China)

机构地区：[1]内蒙古医科大学附属医院泌尿外科,呼和浩特010050

出　　处：《现代泌尿生殖肿瘤杂志》2017年第4期202-206,共5页Journal of Contemporary Urologic and Reproductive Oncology

基　　金：内蒙古自治区自然科学基金(2015MS08115);内蒙古医科大学附属医院重大科研项目(NYFY ZD 2014011)

摘　　要：目的探讨肾透明细胞癌(clear cell renal cell carcinoma,ccRCC)患者术前血清高敏C反应蛋白(high sensitive C-reactive protein,hs-CRP)和降钙素原(procalcitonin,PCT)水平与肿瘤病理分期、分级的相关性。方法采用ELISA对2014年9月至2016年9月内蒙古医科大学附属医院泌尿外科收治的行肾癌根治术或肾部分切除术的98例ccRCC患者术前血清hs-CRP与PCT水平进行检测,并分析其与肿瘤病理分期、分级的相关性。结果与病理分期为pT_1[0.610(0.006~2.730)mg/L]及pT_2[0.990(0.140~3.120)mg/L]的患者相比较,pT_(3+4)患者的血清hs-CRP水平增高[1.510(0.070~3.940)mg/L],差异有统计学意义(P<0.05);与Fuhrman分级为Grade1~2组患者相比较,Grade3~4组患者血清hs-CRP水平增高[0.270(0.005~2.690)vs 1.410(0.130~3.880)mg/L],差异有统计学意义(P<0.05)。与病理分期为pT_1[0.060(0.001~2.630)ng/ml]组患者相比较,pT_2[0.420(0.023~1.550)ng/ml]和pT_(3+4)[0.480(0.080~2.630)ng/ml]组患者的血清PCT水平增高,差异有统计学意义(P<0.05);与Fuhrman分级为Grade1~2的患者[0.050(0.001~1.220)ng/ml]相比较,Grade3~4[0.270(0.013~2.800)ng/ml]的患者其血清PCT水平增高,差异有统计学意义(P<0.05)。受试者工作曲线分析结果表明,血清hs-CRP水平的阈值为0.652 mg/L(灵敏度94.7%、特异性83.0%),血清PCT水平的阈值为0.086ng/ml(灵敏度82.1%、特异性80.5%)。结论 ccRCC患者术前hs-CRP和PCT水平与肿瘤的病理分期、分级具有相关性。ObjectiveTo evaluate the relationship between preoperative high sensitive C reactive protein(hs CRP),procalcitonin(PCT)levels and tumor stage,tumor grade in patients with clear cell renal cell carcinoma(ccRCC).MethodsThe serum levels of hs CRP and PCT in98ccRCC patients who had undergone either radical or partial nephrectomy at department of urology,first hospital of Inner Mongolia medical university between September2014and September2016were determined by enzyme linked immunosorbent assay(ELISA).Comparison of hs CRP and PCT levels between the subgroups of pathological stage and nuclear grade were evaluated.ResultsHs CRP levels of pT3+4stage[1.510(0.0703.940)mg/L]patients were found to be higher compared to the pT1[0.610(0.0062.730)mg/L]group and pT2[0.990(0.1403.120)mg/L](P<0.05).Similarly,hs CRP levels of Fuhrman grade34patients were found to be higher compared to the Fuhrman grade12[0.270(0.0052.690)vs1.410(0.1303.880)]group(P<0.05).PCT levels of pT2[0.420(0.0231.550)ng/ml],pT3+4[0.480(0.0802.630)ng/ml]were found to be higher compared to the pT1[0.060(0.0012.630)ng/ml](P<0.05).PCT levels of Fuhrman grade34patients were found to be higher compared to the Fuhrman grade12[0.050(0.0011.220)vs0.270(0.0132.800)]group(P<0.05).ROC analysis was performed and cut off values of0.652mg/L(sensitivity94.7%and specificity83.0%)and0.086ng/ml(sensitivity82.1%and specificity80.5%)were detected for hs CRP and PCT,respectively.ConclusionsThere exists a relationship between preoperative hs CRP,PCT levels and tumor stage,tumor grade in patients with.

关 键 词：肾透明细胞癌 高敏C反应蛋白 降钙素原 病理分期 病理分级 

分 类 号：R737.11[医药卫生—肿瘤]